BIBLIOGRAFIA
1. Ramòn Lecumberri, Josè A. Pàramo, Eduardo Rocha, Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica/ the Hematology Journal, 2005; 90:1258-1266.
2. Susanne M. Smorenburg and Cornelis J. F. Van Noorden, The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies,
Pharmacological Reviews, 2001; 53: 93-105.
3. R. J. Ludwig et al.,. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost, 2006; 95: 535-540.
4. Mousa SA., Low-molecular-weight heparin in thrombosis and cancer.Semin Thromb Hemost. 2004 Feb;30 Suppl 1:25-30.
5. Borsig L., et al., Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumour metastasis.Proc Natl Acad Sci USA, 2001; 98: 3352-3357.
6. Marco Presta et al., Antiangiogenetic Activity of Semisynthetic Biotechnological Heparins. Arterioscler Thromb Vasc Biol. 2005; 25:71-76.
7. Zacharsky LR, Ornstein DL, Mamourian AC., Low-molecular-weight heparin and cancer. Semin Thromb Hemost. 2000; 26(suppl 1) : 69-77.
8. Engelberg H., Actions of heparin that may affect the malignant process. Cancer.1999; 85: 257-272.
9. Castelli R, Porro F, Tarsia P., The heparins and cancer: review of clinical trials and biological properties. Vasc Med. 2004 May; 9(3): 205-13.
10. Ramzi S. Cotran, Vinay Kumar, Tucker Collins, Le Basi Patologiche delle Malattie. 2000; VI edizione. Ed Piccin Nuova Libraria S. p. A.
11. Mousa SA., Low-molecular-weight heparin in thrombosis and cancer. Semin Thromb Hemost.2004 Feb; 30 Suppl 1:25-30.
12. Mousa SA, Anti-thrombotics in thrombosis and cancer. Future Oncol.,2005 Jun;1(3):395-403.
13. Mousa SA, Low-molecular-weight heparins in thrombosis and cancer: emerging links. 2004 Summer; 22(2):121-34.
14. Glasmann AB, Jones E, Thrombosis and coagulation abnormalities associated with cancer. Ann Clin Lab Sci, 1994; 24:1-5.
15. Zacharski LR, Ornstein DL, Heparin and cancer. Thromb Haemost, 1998; 80: 1023. 16. Amirkhosravi A, Mousa SA, Amaya M, Francis Jl, Antimetastatic effect of
tinzaparin, a low-molecular-weight heparin. J Thromb Haemost, 2003 Sep; 1(9): 1972-6.
17. Mousa SA, Mohamed S., Anti-angiogenic mechanisms and efficacy of the low molecular-weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep., 2004 Oct; 12(4): 683-8.
18. Ludwig RJ et al., Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res, 2004 Apr; 64(8):2743-50. 19. Brechot JM, Thrombosis and lung cancer. Rev Mal Respir, 2005 Dec; 22(6 Pt 2): 8S33-7.
20. Gao Y, Wei M, Zheng S, Ba X, Hao S, Zeng X, Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to
P-selectin. Journal of Cancer Research and Clinical Oncology, 2006 Apr;132(4): 257-264. Epub 2005 Dec 6.
21. Sato T, Tsujino I, Ikeda D, Ieko M, Nishimura M, Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax, 2006 Nov; 61(11): 1009-10.
22. Bell WR, Starksen NF, Tong S, Porterfield JK, Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. The American Journal of Medicine, 1985 Oct; 79(4): 423-30.
23. Woerner EM, Rowe RL, Trousseau's syndrome. American Family Physician, 1988 Sep ; 38(3) : 195-201.
24. Rickles FR, Edwards RL, Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood, 1983 Jul; 62(1): 14-31.
25. Costantini V, Zackarski LR, Fibrin and cancer. Thromb Haemost, 1993 May 3;
26. Khorana AA, Sahni A, Altland OD, Francis CW, Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol, 2003; 23: 2110-5.
27. Falanga A, Marchetti M, Vignoli A, Pathogenesis of thrombosis in cancer. In: Thrombosis and Cancer, Martin Dunitz Co, 2004. p. 11-29.
28. Lip GYH, Chin BSP, Blann AD, Cancer and the prothrombotic state. Lancet Oncol 2002; 3: 27-34.
29. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny
P, et al., Comparison of low-molecular-weight heparin and warfarin for the
secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study. Arch Intern Med, 2002; 162: 1729-35.
30. Rickles FR, Patierno S, Fernandez PM, Tissue factor, thrombin and cancer. Chest, 2003; 124: 58S-68S.
31. Hagner-Mcwhirter A, Lindahl U, Li J, Biosynthesis of heparin/heparan sulphate: mechanism of epimerization of glucuronyl C-5. The Biochemical Journal, 2000 Apr 1; 347 Pt 1: 69-75.
32. Samoszuk M, Kanakubo E, Chan JK, Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer, 2005 Sep 21; 5:121. 33. Rao LV, Tissue factor as a tumor procoagulant. Cancer Metastasis Rev,
34. Lebeau B, Chastang C, Brechot Jm, Capron F, Dautzenberg B, Delaicements C,
Mornet M, Brun J, Hurdebourcq JP, Lemarie E, Subcutaneous heparin treatment
increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer, 1994; 74: 38-45.
35. Hari G. Garg, B. Taylor Thompson, and Charles A. Hales, Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2000; 279: L779-L789.
36. Spira A. and D.S. Ettinger, Multidisciplinary management of lung cancer.N Engl J Med, 2004; 350(4): p. 379-92.
37.Ferro D, Provasoli A, et al (1990). Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr. Res. 195: 157-167.
38.Mulloy B, Forster MJ, Jones C, Davies DB. (1993). Biochem. J. 293: 849-858. 39.Petitou M, Herault JP, Bernat A, Driguez PA, et al. (1999). Synthesis of Thrombin inhibiting Heparin mimetics without side effects. Nature 398: 417-422.
40. Hartwell LH, Culotti J, Pringle JR, Reid BJ Genetic control of the cell division cycle in yeast. SCIENCE. 1974 JAN 11;183(120):46-51.
41.Mariano Ferrari, Roberto Padrini Farmacologia Clinica Cardiovascolare. Piccin
![() ()= () () () []= () () n 1 Η F X X X X , , , , … … … … =…= , , , , X X X X F n − 1 Η S E = Η = SX Η X , … ⎛⎝⎜⎞⎠⎟ , , X X , … , X 1 1 1 ⎛⎝⎜⎞⎠⎟ ⎛⎝⎜⎞⎠⎟ ⎛⎝⎜⎞⎠⎟ ⎡⎣⎤⎦ ES X X X X , , , , … … … S , , , X X X = ~ ~ ~ N N N , , , () X − EX () () ~ n − 1 S S X](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)